全文获取类型
收费全文 | 47049篇 |
免费 | 3522篇 |
国内免费 | 189篇 |
专业分类
耳鼻咽喉 | 415篇 |
儿科学 | 1523篇 |
妇产科学 | 1203篇 |
基础医学 | 6611篇 |
口腔科学 | 651篇 |
临床医学 | 5051篇 |
内科学 | 9857篇 |
皮肤病学 | 891篇 |
神经病学 | 5559篇 |
特种医学 | 1139篇 |
外科学 | 4247篇 |
综合类 | 380篇 |
一般理论 | 59篇 |
预防医学 | 5677篇 |
眼科学 | 617篇 |
药学 | 2996篇 |
中国医学 | 87篇 |
肿瘤学 | 3797篇 |
出版年
2024年 | 60篇 |
2023年 | 651篇 |
2022年 | 1091篇 |
2021年 | 2149篇 |
2020年 | 1307篇 |
2019年 | 1777篇 |
2018年 | 2039篇 |
2017年 | 1364篇 |
2016年 | 1523篇 |
2015年 | 1677篇 |
2014年 | 2040篇 |
2013年 | 2643篇 |
2012年 | 4223篇 |
2011年 | 4180篇 |
2010年 | 2126篇 |
2009年 | 1867篇 |
2008年 | 2970篇 |
2007年 | 2944篇 |
2006年 | 2809篇 |
2005年 | 2594篇 |
2004年 | 2306篇 |
2003年 | 2055篇 |
2002年 | 1760篇 |
2001年 | 209篇 |
2000年 | 158篇 |
1999年 | 224篇 |
1998年 | 353篇 |
1997年 | 261篇 |
1996年 | 213篇 |
1995年 | 178篇 |
1994年 | 125篇 |
1993年 | 118篇 |
1992年 | 73篇 |
1991年 | 72篇 |
1990年 | 60篇 |
1989年 | 68篇 |
1988年 | 57篇 |
1987年 | 40篇 |
1986年 | 43篇 |
1985年 | 40篇 |
1984年 | 48篇 |
1983年 | 46篇 |
1982年 | 34篇 |
1981年 | 41篇 |
1980年 | 29篇 |
1979年 | 18篇 |
1978年 | 14篇 |
1977年 | 20篇 |
1975年 | 9篇 |
1973年 | 9篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
941.
Fabi Marianna Andreozzi Laura Frabboni Ilaria Dormi Ada Corinaldesi Elena Lami Francesca Cicero Cristina Tchana Bertrand Francavilla Rosa Sprocati Monica Bigucci Barbara Balsamo Claudia Valin Paola Sogno Di Fazzio Giorgia Iughetti Lorenzo Valletta Enrico Marchetti Federico Donti Andrea Lanari Marcello 《Clinical rheumatology》2021,40(4):1507-1514
Clinical Rheumatology - Kawasaki disease (KD) is the most frequent cause of acquired heart disease in children in high-income countries because of coronary artery involvement. Risk factors for... 相似文献
942.
943.
Nicholas E. Ingraham Laura N. Purcell Basil S. Karam R. Adams Dudley Michael G. Usher Christopher A. Warlick Michele L. Allen Genevieve B. Melton Anthony Charles Christopher J. Tignanelli 《Journal of general internal medicine》2021,36(11):3462
BackgroundDespite past and ongoing efforts to achieve health equity in the USA, racial and ethnic disparities persist and appear to be exacerbated by COVID-19.ObjectiveEvaluate neighborhood-level deprivation and English language proficiency effect on disproportionate outcomes seen in racial and ethnic minorities diagnosed with COVID-19.DesignRetrospective cohort studySettingHealth records of 12 Midwest hospitals and 60 clinics in Minnesota between March 4, 2020, and August 19, 2020PatientsPolymerase chain reaction–positive COVID-19 patientsExposuresArea Deprivation Index (ADI) and primary languageMain MeasuresThe primary outcome was COVID-19 severity, using hospitalization within 45 days of diagnosis as a marker of severity. Logistic and competing-risk regression models assessed the effects of neighborhood-level deprivation (using the ADI) and primary language. Within race, effects of ADI and primary language were measured using logistic regression.ResultsA total of 5577 individuals infected with SARS-CoV-2 were included; 866 (n = 15.5%) were hospitalized within 45 days of diagnosis. Hospitalized patients were older (60.9 vs. 40.4 years, p < 0.001) and more likely to be male (n = 425 [49.1%] vs. 2049 [43.5%], p = 0.002). Of those requiring hospitalization, 43.9% (n = 381), 19.9% (n = 172), 18.6% (n = 161), and 11.8% (n = 102) were White, Black, Asian, and Hispanic, respectively. Independent of ADI, minority race/ethnicity was associated with COVID-19 severity: Hispanic patients (OR 3.8, 95% CI 2.72–5.30), Asians (OR 2.39, 95% CI 1.74–3.29), and Blacks (OR 1.50, 95% CI 1.15–1.94). ADI was not associated with hospitalization. Non-English-speaking (OR 1.91, 95% CI 1.51–2.43) significantly increased odds of hospital admission across and within minority groups.ConclusionsMinority populations have increased odds of severe COVID-19 independent of neighborhood deprivation, a commonly suspected driver of disparate outcomes. Non-English-speaking accounts for differences across and within minority populations. These results support the ongoing need to determine the mechanisms that contribute to disparities during COVID-19 while also highlighting the underappreciated role primary language plays in COVID-19 severity among minority groups.Supplementary InformationThe online version contains supplementary material available at 10.1007/s11606-021-06790-w. 相似文献
944.
Falsaperla Raffaele Sciuto Laura La Spina Luisa Sciuto Sarah Praticò Andrea D. Ruggieri Martino 《Metabolic brain disease》2021,36(8):2195-2203
Metabolic Brain Disease - Neonatal seizures (NS) occur in the first 28 days of life; they represent an important emergency that requires a rapid diagnostic work-up to start a prompt... 相似文献
945.
Frech Tracy M. VanBuren John M. Startup Emily Assassi Shervin Bernstein Elana J. Castelino Flavia V. Chung Lorinda Correia Chase Gordon Jessica K. Hant Faye N. Hummers Laura Khanna Dinesh Sandorfi Nora Shah Ami A. Shanmugam Victoria K. Steen Virginia Evnin Luke 《Clinical rheumatology》2021,40(3):965-971
Clinical Rheumatology - The objective of this analysis is to examine whether the severity of systemic sclerosis (SSc)-hand involvement influences patient-reported outcome measure (PROM) completion... 相似文献
946.
Alessandra Elvevi Elena Maria Elli Martina Luc Miki Scaravaglio Fabio Pagni Stefano Ceola Laura Ratti Pietro Invernizzi Sara Massironi 《World journal of gastroenterology : WJG》2022,28(29):3767-3779
Mastocytosis is a rare and heterogeneous disease characterized by various clinical and biological features that affect different prognoses and treatments. The disease is usually divided into 2 principal categories: cutaneous and systemic disease (SM). Clinical features can be related to mast cell (MC) mediator release or pathological MC infiltration. SM is a disease often hard to identify, and the diagnosis is based on clinical, biological, histological, and molecular criteria with different specialists involved in the patient’s clinical work-up. Among all manifestations of the disease, gastrointestinal (GI) symptoms are common, being present in 14%-85% of patients, and can significantly impair the quality of life. Here we review the data regarding GI involvement in SM, in terms of clinical presentations, histological and endoscopic features, the pathogenesis of GI symptoms, and their treatment. 相似文献
947.
Valerio Rosato Antonio Ascione Riccardo Nevola Anna Ludovica Fracanzani Guido Piai Vincenzo Messina Ernesto Claar Carmine Coppola Luca Fontanella Rosa Lombardi Laura Staiano Giovanna Valente Maria Chiara Fascione Chiara Giorgione Annalisa Mazzocca Raffaele Galiero Pasquale Perillo Aldo Marrone Ferdinando Carlo Sasso Luigi Elio Adinolfi Luca Rinaldi 《Journal of viral hepatitis》2022,29(1):26-34
The long-term changes of liver stiffness (LS) in patients who achieve viral clearance after direct-acting anti-HCV therapy remain undefined. We conducted a multicentre prospective study to investigate this aspect. Patients with HCV infection treated with DAAs were enrolled from six Italian centres; they underwent clinical, biochemical, ultrasound and transient elastography evaluations before treatment (T0), 12 weeks (SVR12) and 24 months (T24) after the end of therapy. Among the 516 consecutive patients enrolled, 301 had cirrhosis. LS significantly decreased from T0 to SVR (14.3 vs 11.1 kPa, p = .002), with a progressive reduction until T24 (8.7 kPa, p < .001). However, only patients with steatosis and those who developed HCC did not experience a late improvement in LS. Multivariate analysis of baseline and follow-up variables identified steatosis as the only independent predictor of failure of LS improvement (OR 1.802, p = .013). ROC curve analysis of the association of LS with the risk of developing HCC showed that SVR12 ≥14.0 kPa had the highest accuracy (sensitivity 82%, specificity 99%; AUC: 0.774). Multivariate analysis revealed that LS was the only variable independently associated with an increased risk of developing HCC (OR 6.470, p = .035). Achieving an SVR was associated with a progressive, long-term decline of LS, suggesting a late improvement in liver fibrosis, besides the resolution of inflammation. Fatty liver and the development of HCC interfered with late reduction of LS. Patients with an LS ≥14 kPa at 12 weeks after the end of treatment were at higher risk for developing HCC. 相似文献
948.
Johnson Laura M. Green Harold D. Lu Minggen Stockman Jamila K. Felsher Marisa Roth Alexis M. Wagner Karla D. 《AIDS and behavior》2022,26(9):2866-2880
AIDS and Behavior - Pre-Exposure Prophylaxis (PrEP) health campaigns invite women to talk with their provider, partner, and peers about PrEP, though they do not offer specific guidance about who... 相似文献
949.
Adriana Ahumada Laura Ray n Clara Us n Rafael Ba ares Sonia Alonso Lopez 《World journal of gastroenterology : WJG》2021,27(40):6737-6749
Hepatitis C virus (HCV) chronic infection is associated with fibrosis progression, end-stage liver complications and HCC. Not surprisingly, HCV infection is a leading cause of liver-related morbidity and mortality worldwide. After sustained virological response (SVR), the risk of developing hepatocellular carcinoma is not completely eliminated in patients with established cirrhosis or with advanced fibrosis. Therefore, lifelong surveillance is currently recommended. This strategy is likely not universally cost-effective and harmless, considering that not all patients with advanced fibrosis have the same risk of developing HCC. Factors related to the severity of liver disease and its potential to improve after SVR, the molecular and epigenetic changes that occur during infection and other associated comorbidities might account for different risk levels and are likely essential for identifying patients who would benefit from screening programs after SVR. Efforts to develop predictive models and risk calculators, biomarkers and genetic panels and even deep learning models to estimate the individual risk of HCC have been made in the direct-acting antiviral agents era, when thousands of patients with advanced fibrosis and cirrhosis have reached SVR. These tools could help to identify patients with very low HCC risk in whom surveillance might not be justified. In this review, factors affecting the probability of HCC development after SVR, the benefits and risks of surveillance, suggested strategies to estimate individualized HCC risk and the current evidence to recommend lifelong surveillance are discussed. 相似文献
950.